The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.
|Slideshows|July 6, 2018
- Dermatology Times, July 2018 (Vol. 39, No. 07)
- Volume 39
- Issue 7
Image IQ: When is a biopsy required?
Author(s)Kaivon Sobhani, BS, Eve Lowenstein, MD, PhD
In this quiz, Kaivon Sobhani, B.S., and, Eve Lowenstein, M.D., Ph.D., FAAD, address dermatofibrosarcoma protuberans (DFSP), keloids, hypertrophic scars and dermatofibromas.
Advertisement
Â
Articles in this issue
about 8 years ago
Pricing patients out of healthcare?about 8 years ago
Rare tumors and fibrotic skin lesionsabout 8 years ago
New Drugs Roundup: Dermatologyabout 8 years ago
The top 7 mobile apps in dermatologyabout 8 years ago
Medicine no longer apoliticalabout 8 years ago
Study: Novel 670 nm wavelength works for benign pigmented lesionsabout 8 years ago
I use social media and now I might lose my license?about 8 years ago
Complications low with chemical peels in darker skinabout 8 years ago
Where full-field erbium outshines fractionalAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
3
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
4
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
5